A Study of Cadonilimab (AK104) Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Condition:   Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy Intervention:   Drug: AK104(anti-PD-1/CTLA-4 bi-specific antibody ,intravenously),lenvatinib( targeted VEGFR 1-3、FGFR、PDGFRα, small molecule TKI,orally Sponsors:   RenJi Hospital;   Ruijin Hospital;   Shanghai Zhongshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Condition:   Renal Cell Carcinoma Intervention:   Drug: Sunitinib Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials

A Study of Cadonilimab (AK104) Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Condition:   Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy Intervention:   Drug: AK104(anti-PD-1/CTLA-4 bi-specific antibody ,intravenously),lenvatinib( targeted VEGFR 1-3、FGFR、PDGFRα, small molecule TKI,orally Sponsors:   RenJi Hospital;   Ruijin Hospital;   Shanghai Zhongshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Condition:   Renal Cell Carcinoma Intervention:   Drug: Sunitinib Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials

A Study of Cadonilimab (AK104) Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Condition:   Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy Intervention:   Drug: AK104(anti-PD-1/CTLA-4 bi-specific antibody ,intravenously),lenvatinib( targeted VEGFR 1-3、FGFR、PDGFRα, small molecule TKI,orally Sponsors:   RenJi Hospital;   Ruijin Hospital;   Shanghai Zhongshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Condition:   Renal Cell Carcinoma Intervention:   Drug: Sunitinib Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials

A Study of Cadonilimab (AK104) Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Condition:   Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy Intervention:   Drug: AK104(anti-PD-1/CTLA-4 bi-specific antibody ,intravenously),lenvatinib( targeted VEGFR 1-3、FGFR、PDGFRα, small molecule TKI,orally Sponsors:   RenJi Hospital;   Ruijin Hospital;   Shanghai Zhongshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Condition:   Renal Cell Carcinoma Intervention:   Drug: Sunitinib Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 12, 2023 Category: Research Source Type: clinical trials

Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
Condition:   Renal Cell Carcinoma Intervention:   Drug: Pembrolizumab injection Sponsor:   University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials